Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have been given an average recommendation of “Hold” by the six analysts that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $14.00.

AGEN has been the topic of several recent research reports. Wall Street Zen raised shares of Agenus from a “strong sell” rating to a “hold” rating in a report on Thursday, May 22nd. B. Riley reaffirmed a “buy” rating on shares of Agenus in a report on Monday, April 21st. HC Wainwright raised shares of Agenus from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Wednesday, June 4th. Finally, Robert W. Baird upped their price objective on shares of Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a report on Wednesday, June 4th.

Agenus Trading Up 15.3%

Shares of Agenus stock opened at $5.95 on Monday. Agenus has a 12-month low of $1.38 and a 12-month high of $18.74. The firm has a market capitalization of $163.13 million, a price-to-earnings ratio of -0.53 and a beta of 1.43. The firm’s 50 day simple moving average is $2.97 and its two-hundred day simple moving average is $2.96.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The company had revenue of $24.07 million for the quarter, compared to analyst estimates of $26.38 million. On average, sell-side analysts predict that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Agenus

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Agenus by 17.7% in the 4th quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 4,924 shares during the last quarter. Apollon Wealth Management LLC raised its position in Agenus by 25.0% in the first quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 5,000 shares during the period. Corton Capital Inc. purchased a new stake in Agenus in the fourth quarter valued at approximately $36,000. Charles Schwab Investment Management Inc. raised its position in Agenus by 32.8% in the first quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company’s stock valued at $96,000 after purchasing an additional 15,731 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Agenus in the fourth quarter valued at approximately $51,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.